ND047
/ Numab, Boehringer Ingelheim
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
September 25, 2025
Numab Therapeutics AG…announced today that Boehringer Ingelheim has advanced its novel T cell engager for the treatment of lung and gastrointestinal (GI) cancers resulting from a collaboration with Numab into preclinical development.
(GlobeNewswire)
New molecule • Gastrointestinal Cancer
1 to 1
Of
1
Go to page
1